|
Market Closed -
Nasdaq
16:00:00 2026-10-19 EDT
|
5-day change | 1st Jan Change | ||
| 0.6001 USD | -3.86% |
|
-19.20% | -79.09% |
| 10-14 | Tempest Therapeutics, Inc. Announces Appointment of John W. Frederick as Director | CI |
| 10-07 | Sensorion: Louis J. Arcudi III appointed chief financial officer |  |
Company Valuation: Tempest Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 36.49 | 12.09 | 84.69 | 36.42 | 14.14 | 9.926 | - |
| Change | - | -66.85% | 600.22% | -57% | -61.17% | -29.81% | - |
| Enterprise Value (EV) | 36.49 | 12.09 | 84.69 | 36.42 | 14.14 | 9.926 | 9.926 |
| Change | - | -66.85% | 600.22% | -57% | -61.17% | -29.81% | 0% |
| P/E | - | -0.37x | -2.3x | -0.56x | -0.45x | -0.21x | -0.67x |
| PBR | - | - | - | - | - | - | - |
| PEG | - | - | 0.1x | 0x | 0x | 0x | 0x |
| Capitalization / Revenue | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / EBIT | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | - | -40.17 | -24.83 | -19.5 | -6.33 | -2.85 | -0.9 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA | -26.99 | -34.64 | -28.78 | - | -26.31 | - | - |
| EBIT | -26.99 | -34.64 | -29.16 | -42.03 | -26.58 | - | - |
| Net income | - | -35.71 | -29.49 | -41.84 | -26.26 | - | - |
| Net Debt | - | - | - | - | - | - | - |
| Reference price 2 | 68.6400 | 14.9500 | 57.2000 | 10.8485 | 2.8700 | 0.6001 | 0.6001 |
| Nbr of stocks (in thousands) | 532 | 809 | 1,481 | 3,357 | 4,927 | 16,540 | - |
| Announcement Date | 3/29/22 | 3/22/23 | 3/19/24 | 3/27/25 | 3/30/26 | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.22x | - | - | - | 10.32M | |
| 18.77x | 6.69x | 13.41x | 1.58% | 65B | |
| 35.3x | 6.27x | 18.74x | 0.92% | 51.2B | |
| 27.56x | 7.53x | 23.83x | 0.05% | 51.19B | |
| 34.01x | 3.32x | 14.33x | -.--% | 43.93B | |
| 48.9x | 5.59x | 30.73x | -.--% | 41.96B | |
| -18.47x | 189.62x | -19.51x | -.--% | 38.14B | |
| 28.97x | 8.21x | 21.25x | 0.37% | 33.24B | |
| 29.19x | 6.17x | 16.01x | -.--% | 25.2B | |
| 30.74x | 5.69x | 19.09x | -.--% | 22.5B | |
| Average | 23.47x | 26.57x | 15.32x | 0.32% | 37.24B | |
| Weighted average by Cap. | 25.97x | 25.01x | 15.48x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- TPST Stock
- Valuation Tempest Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
